Vertex Sits On $1.4bn Cash, Seeks External Innovation Away From CF
Executive Summary
Vertex – a company currently leading the lucrative cystic fibrosis market and set to retain command of this arena into the foreseeable future – is preparing to replicate its CF success in another therapy area.
You may also be interested in...
Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.